GSK Lamictal monotherapy for seizures
Executive Summary
GlaxoSmithKline's Lamictal (lamotrigine) approved by FDA Jan. 14 for use as monotherapy in the treatment of partial seizures in patients 16 years and older. Originally approved in December 1996 as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, Lamictal has been part of GSK's plan to fill in its nearer-term pipeline through line extensions (1"The Pink Sheet" Dec. 15, 2003, p. 29)...
You may also be interested in...
GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come
GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.